DNBSEQ-G99 Debut in France at MICROBES 2023 Event

Rennes, France

Share

DNBSEQ-G99 Debut in France at MICROBES 2023 Event
DNBSEQ-G99 Debut in France at MICROBES 2023 Event

Freshly available to the European market, the DNBSEQ-G99, our new mid-throughput sequencer, has debuted in France at the MICROBES 2023 event, held in the Couvent de Jacobins in Rennes.

This microbiology-focused event provides the platform for the first showcase of the G99 in France, our latest sequencer designed for mid-throughput NGS projects, and well-suited for metagenomics analysis.

The G99 marks a significant leap forward, offering low to mid-throughput sequencing capabilities while maintaining exceptional accuracy. It caters to the growing needs of researchers and genomics professionals, opening new avenues for a deeper understanding of microbial communities.

During the event, our MGI team was honoured to participate in an exclusive symposium, highlighting the crucial importance of human microbiota analysis in advancing science and developing innovative health tools. Our experts shared key insights into the contribution of human microbiota to medical research and discussed future opportunities to leverage this knowledge in creating groundbreaking health solutions.

Our participation at Microbes in Rennes and our involvement in the symposium underscore our ongoing commitment to advancing metagenomics and our desire to contribute meaningfully to scientific research.

For more information on the G99 and our latest advancements, please visit the G99 webpage.

Freshly available to the European market, the DNBSEQ-G99, our new mid-throughput sequencer, has debuted in France at the MICROBES 2023 event, held in the Couvent de Jacobins in Rennes.

This microbiology-focused event provides the platform for the first showcase of the G99 in France, our latest sequencer designed for mid-throughput NGS projects, and well-suited for metagenomics analysis.

The G99 marks a significant leap forward, offering low to mid-throughput sequencing capabilities while maintaining exceptional accuracy. It caters to the growing needs of researchers and genomics professionals, opening new avenues for a deeper understanding of microbial communities.

During the event, our MGI team was honoured to participate in an exclusive symposium, highlighting the crucial importance of human microbiota analysis in advancing science and developing innovative health tools. Our experts shared key insights into the contribution of human microbiota to medical research and discussed future opportunities to leverage this knowledge in creating groundbreaking health solutions.

Our participation at Microbes in Rennes and our involvement in the symposium underscore our ongoing commitment to advancing metagenomics and our desire to contribute meaningfully to scientific research.

For more information on the G99 and our latest advancements, please visit the G99 webpage.

Freshly available to the European market, the DNBSEQ-G99, our new mid-throughput sequencer, has debuted in France at the MICROBES 2023 event, held in the Couvent de Jacobins in Rennes.

This microbiology-focused event provides the platform for the first showcase of the G99 in France, our latest sequencer designed for mid-throughput NGS projects, and well-suited for metagenomics analysis.

The G99 marks a significant leap forward, offering low to mid-throughput sequencing capabilities while maintaining exceptional accuracy. It caters to the growing needs of researchers and genomics professionals, opening new avenues for a deeper understanding of microbial communities.

During the event, our MGI team was honoured to participate in an exclusive symposium, highlighting the crucial importance of human microbiota analysis in advancing science and developing innovative health tools. Our experts shared key insights into the contribution of human microbiota to medical research and discussed future opportunities to leverage this knowledge in creating groundbreaking health solutions.

Our participation at Microbes in Rennes and our involvement in the symposium underscore our ongoing commitment to advancing metagenomics and our desire to contribute meaningfully to scientific research.

For more information on the G99 and our latest advancements, please visit the G99 webpage.

Freshly available to the European market, the DNBSEQ-G99, our new mid-throughput sequencer, has debuted in France at the MICROBES 2023 event, held in the Couvent de Jacobins in Rennes.

This microbiology-focused event provides the platform for the first showcase of the G99 in France, our latest sequencer designed for mid-throughput NGS projects, and well-suited for metagenomics analysis.

The G99 marks a significant leap forward, offering low to mid-throughput sequencing capabilities while maintaining exceptional accuracy. It caters to the growing needs of researchers and genomics professionals, opening new avenues for a deeper understanding of microbial communities.

During the event, our MGI team was honoured to participate in an exclusive symposium, highlighting the crucial importance of human microbiota analysis in advancing science and developing innovative health tools. Our experts shared key insights into the contribution of human microbiota to medical research and discussed future opportunities to leverage this knowledge in creating groundbreaking health solutions.

Our participation at Microbes in Rennes and our involvement in the symposium underscore our ongoing commitment to advancing metagenomics and our desire to contribute meaningfully to scientific research.

For more information on the G99 and our latest advancements, please visit the G99 webpage.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

MGI-tech stands at the forefront of the biotechnological revolution, having firmly established its dominance in the field of gene sequencing and life science innovation. With the recent accolade of the Globee® for Medical Equipment, awarded to their DNBSEQ-T20×2 gene sequencing platform, MGI's trajectory towards pioneering unprecedented advancements in genetics is clear and commendable.

A Beacon of Innovation: The Globee® Awards The Globee® Awards shine a spotlight on entities that redefine industry standards through ingenuity and ambition. As a platform recognizing the zenith of business excellence, it honors MGI among other titans like Amazon and IBM, underscoring the company’s vision and execution in propelling the genetic industry forward. Garnering this award for the second time in succession, MGI reaffirms its stature as an innovator par excellence.

The DNBSEQ-T20×2: A Technological Marvel February 2023 saw the launch of MGI's DNBSEQ-T20×2, affectionately termed 'T20*', which epitomizes the cutting edge of gene sequencing technology. Engineered for ultra-high-throughput sequencing, the T20* is a beacon of affordability and efficiency, democratizing genome sequencing and catalyzing a new era of medical breakthroughs in health monitoring and disease prevention.

The Economic and Healthcare Revolution A crucial milestone achieved by the T20* is the reduction of genome sequencing costs to under $100, a leap forward in making personalized medicine a universal standard. This seismic shift promises to accelerate our understanding of the human genome, with far-reaching implications for medical research and the broader healthcare industry.

MGI's Visionary Leadership and Future Aspirations Duncan Yu, President of MGI, articulates the company's pride and reinforced commitment to advancing research and improving healthcare outcomes following the Globee® victory. The company’s relentless drive to break barriers in sequencing capacity and cost-efficiency resonates through its continued innovations and strategic partnerships, poised to propel the life science industry towards a future where precision medicine is not just a possibility, but a norm.

Conclusion: MGI's journey is marked by persistent pursuit of excellence and innovation. With its unique DNBSEQ technology and the T20* sequencing platform, MGI is not merely participating in the life science industry; it is actively sculpting its growth and direction. As MGI continues to forge alliances and foster advancements, its impact transcends the company itself, positioning it as a pivotal architect in the evolving narrative of global healthcare and life science.

MGI-tech stands at the forefront of the biotechnological revolution, having firmly established its dominance in the field of gene sequencing and life science innovation. With the recent accolade of the Globee® for Medical Equipment, awarded to their DNBSEQ-T20×2 gene sequencing platform, MGI's trajectory towards pioneering unprecedented advancements in genetics is clear and commendable.

A Beacon of Innovation: The Globee® Awards The Globee® Awards shine a spotlight on entities that redefine industry standards through ingenuity and ambition. As a platform recognizing the zenith of business excellence, it honors MGI among other titans like Amazon and IBM, underscoring the company’s vision and execution in propelling the genetic industry forward. Garnering this award for the second time in succession, MGI reaffirms its stature as an innovator par excellence.

The DNBSEQ-T20×2: A Technological Marvel February 2023 saw the launch of MGI's DNBSEQ-T20×2, affectionately termed 'T20*', which epitomizes the cutting edge of gene sequencing technology. Engineered for ultra-high-throughput sequencing, the T20* is a beacon of affordability and efficiency, democratizing genome sequencing and catalyzing a new era of medical breakthroughs in health monitoring and disease prevention.

The Economic and Healthcare Revolution A crucial milestone achieved by the T20* is the reduction of genome sequencing costs to under $100, a leap forward in making personalized medicine a universal standard. This seismic shift promises to accelerate our understanding of the human genome, with far-reaching implications for medical research and the broader healthcare industry.

MGI's Visionary Leadership and Future Aspirations Duncan Yu, President of MGI, articulates the company's pride and reinforced commitment to advancing research and improving healthcare outcomes following the Globee® victory. The company’s relentless drive to break barriers in sequencing capacity and cost-efficiency resonates through its continued innovations and strategic partnerships, poised to propel the life science industry towards a future where precision medicine is not just a possibility, but a norm.

Conclusion: MGI's journey is marked by persistent pursuit of excellence and innovation. With its unique DNBSEQ technology and the T20* sequencing platform, MGI is not merely participating in the life science industry; it is actively sculpting its growth and direction. As MGI continues to forge alliances and foster advancements, its impact transcends the company itself, positioning it as a pivotal architect in the evolving narrative of global healthcare and life science.

MGI-tech stands at the forefront of the biotechnological revolution, having firmly established its dominance in the field of gene sequencing and life science innovation. With the recent accolade of the Globee® for Medical Equipment, awarded to their DNBSEQ-T20×2 gene sequencing platform, MGI's trajectory towards pioneering unprecedented advancements in genetics is clear and commendable.

A Beacon of Innovation: The Globee® Awards The Globee® Awards shine a spotlight on entities that redefine industry standards through ingenuity and ambition. As a platform recognizing the zenith of business excellence, it honors MGI among other titans like Amazon and IBM, underscoring the company’s vision and execution in propelling the genetic industry forward. Garnering this award for the second time in succession, MGI reaffirms its stature as an innovator par excellence.

The DNBSEQ-T20×2: A Technological Marvel February 2023 saw the launch of MGI's DNBSEQ-T20×2, affectionately termed 'T20*', which epitomizes the cutting edge of gene sequencing technology. Engineered for ultra-high-throughput sequencing, the T20* is a beacon of affordability and efficiency, democratizing genome sequencing and catalyzing a new era of medical breakthroughs in health monitoring and disease prevention.

The Economic and Healthcare Revolution A crucial milestone achieved by the T20* is the reduction of genome sequencing costs to under $100, a leap forward in making personalized medicine a universal standard. This seismic shift promises to accelerate our understanding of the human genome, with far-reaching implications for medical research and the broader healthcare industry.

MGI's Visionary Leadership and Future Aspirations Duncan Yu, President of MGI, articulates the company's pride and reinforced commitment to advancing research and improving healthcare outcomes following the Globee® victory. The company’s relentless drive to break barriers in sequencing capacity and cost-efficiency resonates through its continued innovations and strategic partnerships, poised to propel the life science industry towards a future where precision medicine is not just a possibility, but a norm.

Conclusion: MGI's journey is marked by persistent pursuit of excellence and innovation. With its unique DNBSEQ technology and the T20* sequencing platform, MGI is not merely participating in the life science industry; it is actively sculpting its growth and direction. As MGI continues to forge alliances and foster advancements, its impact transcends the company itself, positioning it as a pivotal architect in the evolving narrative of global healthcare and life science.

MGI-tech stands at the forefront of the biotechnological revolution, having firmly established its dominance in the field of gene sequencing and life science innovation. With the recent accolade of the Globee® for Medical Equipment, awarded to their DNBSEQ-T20×2 gene sequencing platform, MGI's trajectory towards pioneering unprecedented advancements in genetics is clear and commendable.

A Beacon of Innovation: The Globee® Awards The Globee® Awards shine a spotlight on entities that redefine industry standards through ingenuity and ambition. As a platform recognizing the zenith of business excellence, it honors MGI among other titans like Amazon and IBM, underscoring the company’s vision and execution in propelling the genetic industry forward. Garnering this award for the second time in succession, MGI reaffirms its stature as an innovator par excellence.

The DNBSEQ-T20×2: A Technological Marvel February 2023 saw the launch of MGI's DNBSEQ-T20×2, affectionately termed 'T20*', which epitomizes the cutting edge of gene sequencing technology. Engineered for ultra-high-throughput sequencing, the T20* is a beacon of affordability and efficiency, democratizing genome sequencing and catalyzing a new era of medical breakthroughs in health monitoring and disease prevention.

The Economic and Healthcare Revolution A crucial milestone achieved by the T20* is the reduction of genome sequencing costs to under $100, a leap forward in making personalized medicine a universal standard. This seismic shift promises to accelerate our understanding of the human genome, with far-reaching implications for medical research and the broader healthcare industry.

MGI's Visionary Leadership and Future Aspirations Duncan Yu, President of MGI, articulates the company's pride and reinforced commitment to advancing research and improving healthcare outcomes following the Globee® victory. The company’s relentless drive to break barriers in sequencing capacity and cost-efficiency resonates through its continued innovations and strategic partnerships, poised to propel the life science industry towards a future where precision medicine is not just a possibility, but a norm.

Conclusion: MGI's journey is marked by persistent pursuit of excellence and innovation. With its unique DNBSEQ technology and the T20* sequencing platform, MGI is not merely participating in the life science industry; it is actively sculpting its growth and direction. As MGI continues to forge alliances and foster advancements, its impact transcends the company itself, positioning it as a pivotal architect in the evolving narrative of global healthcare and life science.

DNBSEQ-G99

MICROBIOLOGY

HUMAN MICROBIOTA ANALYSIS

MID THROUGHPUT SEQUENCER

MICROBES

Share this article :

Share

More Events

Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024

Mar 18, 2024

Join MGI at Spatial Biology UK 2024

Discover Genomic Innovations with MGI at Spatial Biology UK 2024! Join us on March 18th-19th at booth 15 at Novotel London West. Don't miss out!

Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference

Jan 27, 2024

Join us at EACR-AACR-IACR Basic and Translational Research Conference

Join us at booth 5 during the EACR-AACR-IACR Basic and Translational Research Conference with the MGI Team in Dublin, Ireland from February 27-29.

Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January

Jan 24, 2024

Join us at The Festival of Genomics & Biodata in January

Join us at booth 98 with MGI Tech during The Festival of Genomics & Biodata on January 24th-25th, 2024, at ExCeL in London.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.